Arcus Biosciences and Gilead Sciences recently discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies for domvanalimab and zimberelimab in metastatic non-small cell lung cancer after a ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers. Grossman is currently chief medical ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...

Arcus Biosciences aims to develop therapies that harness the immune system to fight cancer. Its research focuses on several new drug candidates that may improve outcomes for patients with cancers like ...

The transaction value is based on the SEC Form 4 weighted average purchase price ($20.76) for the trades executed. How significant was this sale relative to Jaen Juan C.'s historical trading? This was ...

Vancouver, British Columbia--(Newsfile Corp. - January 29, 2026) - Arcus Development Group Inc. (TSXV: ADG) ("Arcus" or the "Company") announces that it has completed a $2 million non-brokered unit ...

82,997 shares were sold indirectly on Dec. 4, 2025, for a transaction value of ~$2.1 million based on a weighted average sale price of $24.71 per share. The sale represented 5.91% of total holdings, ...